Hisashi Hidaka, Yasuko Iwakiri – 6 October 2014

Chunping Wang, Huaming Wang, Wuwei Yang, Kaiwen Hu, Hui Xie, Ke‐Qin Hu, Wenlin Bai, Zheng Dong, Yinying Lu, Zhen Zeng, Min Lou, Hong Wang, Xudong Gao, Xiujuan Chang, Linjing An, Jianhui Qu, Jin Li, Yongping Yang – 6 October 2014 – Radiofrequency ablation (RFA) is considered a curative treatment option for hepatocellular carcinoma (HCC). Growing data have demonstrated that cryoablation represents a safe and effective alternative therapy for HCC, but no randomized controlled trial (RCT) has been reported to compare cryoablation with RFA in HCC treatment.

Wei Zhang, Richard Kim, Cristiano Quintini, Koji Hashimoto, Masato Fujiki, Teresa Diago, Bijan Eghtesad, Charles Miller, John Fung, Ann Tan, K. V. Narayanan Menon, Federico Aucejo – 6 October 2014 – Vascular endothelial growth factor (VEGF) is pivotal in the development of hepatocellular carcinoma (HCC). Studies have demonstrated the prognostic value of circulating VEGF levels in patients undergoing liver resection or locoregional therapy (LRT) for HCC.

Chunping Wang, Huaming Wang, Wuwei Yang, Kaiwen Hu, Hui Xie, Ke‐Qin Hu, Wenlin Bai, Zheng Dong, Yinying Lu, Zhen Zeng, Min Lou, Hong Wang, Xudong Gao, Xiujuan Chang, Linjing An, Jianhui Qu, Jin Li, Yongping Yang – 6 October 2014 – Radiofrequency ablation (RFA) is considered a curative treatment option for hepatocellular carcinoma (HCC). Growing data have demonstrated that cryoablation represents a safe and effective alternative therapy for HCC, but no randomized controlled trial (RCT) has been reported to compare cryoablation with RFA in HCC treatment.

Filipe Nery, Sylvie Chevret, Bertrand Condat, Emmanuelle de Raucourt, Larbi Boudaoud, Pierre‐Emmanuel Rautou, Aurelie Plessier, Dominique Roulot, Cendrine Chaffaut, Valerie Bourcier, Jean‐Claude Trinchet, Dominique‐Charles Valla, on behalf of Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire – 6 October 2014 – In cirrhosis, portal vein thrombosis (PVT) could be a cause or a consequence of the progression of liver disease.

Rajesh Ramanathan, Amit Sharma, Matthew Kaspar, Martha Behnke, Shiyu Song, R. Todd Stravitz, Adrian Cotterell, Marc Posner, Robert A. Fisher – 6 October 2014 – Acute rejection after liver transplantation occurs in one‐third of all recipients and can be managed with conventional rejection therapy in the majority of cases. In rare instances, patients with severe acute rejection may be refractory to or have contraindications for conventional therapies.

Imir G. Metushi, M. Anthony Hayes, Jack Uetrecht – 6 October 2014 – The mechanism of idiosyncratic drug‐induced liver injury (IDILI) remains poorly understood, to a large degree because of the lack of a valid animal model. Recently, we reported an animal model in which treatment of female C57BL/6 mice with amodiaquine (AQ) resulted in mild liver injury with a delayed onset and resolution despite continued treatment. Such adaptation is a common outcome in the IDILI caused by drugs that can cause liver failure.

Ira Hofer, John Spivack, Miguel Yaport, Jeron Zerillo, David L. Reich, David Wax, Samuel DeMaria – 4 October 2014 – The anesthesiologist has been recognized as an integral member of the liver transplant team, and previous studies have demonstrated that inter‐anesthesiologist variability can be a driver of outcomes for high‐risk patients. We hypothesized that anesthesiologist experience, defined as the number of previous liver transplants performed at our institution, the Icahn School of Medicine at Mount Sinai, would be independently associated with outcomes for liver transplant patients.

1 October 2014

Michael Torbenson, Peter Schirmacher – 1 October 2014